NEW YORK (GenomeWeb) – Metamark Genetics said today that it has signed a deal to become the exclusive worldwide sales agent for Hologic's Progensa PCA3 prostate cancer assay. The companies have also agreed to collaborate on a second-generation version of the test.

The Progensa test is designed to measure overexpression of prostate cancer antigen 3 (PCA3) RNA in urine samples and was cleared by the US Food and Drug Administration in 2012 for use on Hologic's semi-automated DTS system.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.